- 26 abstracts on Cosentyx® (secukinumab) in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) will be presented at the Annual European Congress of Rheumatology (EULAR 2018)[1]
- Breadth of data covers updates on radiographic progression, quality of life and real-world evidence of patient satisfaction with Cosentyx - including 9 abstracts on AS, putting Novartis at the forefront of driving scientific understanding of this debilitating disease[1]
- Cosentyx specifically inhibits IL-17A, a cornerstone cytokine involved in the development of AS and PsA[2]-[6]. To date, Cosentyx has been prescribed to more than 150,000 patients to worldwide[7]
Basel, June 13, 2018 - Novartis will attend the Annual European Congress of Rheumatology (EULAR 2018) with 26 accepted abstracts reinforcing the roles of Cosentyx® (secukinumab) and IL-17A, cornerstone cytokine in the development of ankylosing spondylitis (AS) and psoriatic arthritis (PsA)[1]. EULAR 2018 will be taking place June 13-16, in Amsterdam, Netherlands.
"For patients living with PsA and AS it is crucial to have therapy options that could help slow down the disease and maintain mobility," said Professor Robert Landewé, Professor of Rheumatology, Academic Medical Centre, Amsterdam, the Netherlands. "The strong data flow on IL-17A at EULAR enhances scientific understanding and advances knowledge on how to best manage these progressive and painful diseases."
"I would like to thank the patients who participated in our trials as well as the investigators and sites who worked with us to run the studies being presented at EULAR 2018," said Eric Hughes, Global Development Unit Head, Immunology, Hepatology and Dermatology. "Collaboration is a key component in driving scientific understanding of spondyloarthritis forward, broadening treatment options for clinicians and, ultimately, improving patient outcomes."
Abstracts accepted at EULAR 2018 include new radiographic progression data in AS and PsA, as well as real-world evidence of patient satisfaction with Cosentyx[1].
Inhibition of radiographic progression in PsA
FUTURE 5 radiographic data show Cosentyx inhibits progression of psoriatic arthritis (PsA) out to Week 24[8]. Radiographic progression in PsA may lead to mobility loss, and even to disability, a major patient concern[9]. (Abstract: Van der Heijde D et al., Subcutaneous secukinumab inhibits radiographic progression in psoriatic arthritis: analysis by prior anti-TNF therapy and concomitant methotrexate use.) Link
No radiographic progression in AS
Data from MEASURE 1 show almost 80% of ankylosing spondylitis (AS) patients on Cosentyx have no radiographic progression of the spine at 4 years[10]. (Abstract: Baraliakos X et al., Secukinumab demonstrates low radiographic progression and sustained efficacy through 4 years in patients with active ankylosing spondylitis.) Link
Patient satisfaction with Cosentyx in AS
Real-world evidence shows that over 90% of AS patients who were treated with Cosentyx for 3 months or more were satisfied with their overall symptom improvement and most patients (74%) indicated overall symptom improvement to be better with Cosentyx compared to their previous treatment[11]. (Abstract: Magrey M et al. Treatment experience and satisfaction in ankylosing spondylitis patients treated with secukinumab: results from a US web-based survey.) Link
Sustainable efficacy and safety with Cosentyx through 4 years in AS
Data from MEASURE 2 study demonstrate Cosentyx provides sustained improvement in signs and symptoms of AS through 4 years with a consistent and favorable safety profile[12]. (Abstract: Marzo-Ortega H et al. Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 4-year results from the Phase III trial, MEASURE 2.) Link
About Cosentyx (secukinumab)
Cosentyx is the first fully-human biologic that specifically inhibits IL-17A, a cornerstone cytokine involved in the inflammation and development of AS, PsA and psoriasis[2]-[6]. IL-17A is produced by various cells from both the innate immune system (which can be triggered by mechanical stress) and the adaptive immune system[6]. By acting directly on IL-17A, Cosentyx inhibits the disease irrespective of the source of IL-17A.
These data add to a growing body of evidence showing the unique position of Cosentyx with long-lasting efficacy and a proven safety profile to treat AS, PsA and moderate-to-severe psoriasis[13]-[16]. To date, Cosentyx has been prescribed to more than 150,000 patients worldwide[7].
Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2017, the Group achieved net sales of USD 49.1 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 124,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com
References
[1] The Annual European Congress of Rheumatology - List of Accepted Abstracts. Available at: https://b-com.mci-group.com/AbstractList/EULAR2018.aspx. Last accessed June 2018.
[2] Cosentyx Summary of Product Characteristics. Novartis Europharm Limited. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003729/human_med_001832.jsp&mid=WC0b01ac058001d124. Last accessed June 2018.
[3] Smith JA et al. Review: The Interleukin 23/Interleukin 17 Axis in Spondyloarthritis Pathogenesis: Th17 and Beyond. Arthritis Rheumatol 2014; 66: 231-41.
[4] Nestle FO et al. Mechanisms of disease psoriasis. N Eng J Med 2009; 361: 496-509.
[5] Girolomoni G et al. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol 2012; 167: 717-24.
[6] Schett G et al. Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol 2017 ;13(12): 731-741.
[7] Novartis. Data on file.
[8] Van der Heijde D et al. Subcutaneous secukinumab inhibits radiographic progression in psoriatic arthritis: analysis by prior anti-TNF therapy and concomitant methotrexate use. Abstract presented at the EULAR 2018 Annual Meeting, Amsterdam, Netherlands. 15 June 2018.
[9] Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs 2014; 74: 423-441.
[10] Baraliakos X et al. Secukinumab demonstrates low radiographic progression and sustained efficacy through 4 years in patients with active ankylosing spondylitis. Abstract presented at the EULAR 2018 Annual Meeting, Amsterdam, Netherlands. 16 June 2018.
[11] Magrey M et al. Treatment experience and satisfaction in ankylosing spondylitis patients treated with secukinumab: results from a US web-based survey. Abstract presented at the EULAR 2018 Annual Meeting, Amsterdam, Netherlands. 16 June 2018.
[12] Marzo-Ortega H et al. Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 4-year results from the Phase III trial, MEASURE 2. Abstract presented at the EULAR 2018 Annual Meeting, Amsterdam, Netherlands. 16 June 2018.
[13] Bissonnette R et al. Secukinumab Demonstrates High Sustained Efficacy and a Favorable Safety Profile in Patients with Moderate to Severe Psoriasis through 5 Years of Treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. ePub ahead of print. doi:10.1111/jdv.14878.
[14] Reich K et al. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2017; 176: 752-58.
[15] Mease PJet al. Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis through 3 years: efficacy and safety results from a phase 3 trial. Ann Rheum Dis. 2017; 76: 952-953.
[16] Braun J et al. Secukinumab demonstrates low radiographic progression and sustained efficacy through 4 years in patients with active ankylosing spondylitis. Late breaking abstract presented at the 2017 ACR/ARHP Annual Meeting, San Diego, USA. 7th November 2017.
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations@novartis.com
| Eric Althoff Novartis Global Media Relations +41 61 324 7999 (direct) +41 79 593 4202 (mobile) eric.althoff@novartis.com | Friedrich von Heyl Novartis Global Pharma Communications +41 61 324 8984 (direct) +41 79 749 0286 (mobile) friedrich.vonheyl@novartis.com |
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com
| Central | North America | ||
| Samir Shah | +41 61 324 7944 | Richard Pulik | +1 212 830 2448 |
| Pierre-Michel Bringer | +41 61 324 1065 | Cory Twining | +1 212 830 2417 |
| Thomas Hungerbuehler | +41 61 324 8425 | ||
| Isabella Zinck | +41 61 324 7188 |
